Cellular and Molecular mechanisms of ATRA inhibition of osteoblast-induced MDS development

NARRATIVE We showed that activation of -catenin in osteoblasts leads to MDS and occurs in 38% of MDS patients. ATRA is reported to inhibit -catenin signaling. Our preliminary data show that inhibition of -catenin signaling in 14 such patients by ATRA improves hematologic phenotype and treats MDS in mice. We aim to dissect molecularly and genetically in mouse and xenograft models the specificity of the inhibitory action of ATRA in this type of osteoblast-induced MDS to explore its potential use in these patients.